Multiple Antioxidants in the Prevention and Treatment of Parkinson’s Disease

REFERENCES

• Olanow CW: “Neurodegeneration and Neuroprotection in Parkinson’s Disease.”New York: Academic Press, 1996.
   Google Scholar
• Moghal S, Rajput AH, D’Arcy C, Rajput R: Prevalence of movement disorders in elderly community residents. Neuroepidemiology 13: 175–178, 1994.
   PubMedGoogle Scholar
• Mena I, Horiuchi K, Burke K, Cotzia GC: Chronic manganese poisoning. Individual susceptibility and absorbtion of iron. Neurology 19: 1000–1006, 1969.
   PubMed Web of Science ®Google Scholar
• Ballard PA, Tetrud JW, Langston JW: Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35: 949–956, 1985.
   PubMed Web of Science ®Google Scholar
• Langston J: Epidemiology versus genetics in Parkinson’s disease: Progress in resolving an age-old debate. Ann of Neurol 44: 545–552, 1998.
   Google Scholar
• Golbe LI, Farrell T, Davis PH: Case-control survey of early life dietary factors in Parkinson’s disease. Arch Neurol 45: 1350–1353, 1988.
   PubMedGoogle Scholar
• Seidler A, Hellenbrand W, Robra B-P, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E: Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology 46: 1275–1284, 1996.
   PubMed Web of Science ®Google Scholar
• Zhang Z-X, Anderson D, Lavine L, Mantel N: Patterns of acquiring parkinsonism-dementia complex on Guam. 1944 through 1985. Arch Neurol 47: 1019–1024, 1990.
   PubMedGoogle Scholar
• de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, van der Meche FG, Hofman A: Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 54: 762–765, 1997.
   PubMed Web of Science ®Google Scholar
• Le Couteur DG, Leighton PW, McCann SJ, Pond S: Association of a polymorphism in the dopamine-transporter gene with Parkinson’s disease. Movement Disord 12: 760–763, 1997.
   PubMedGoogle Scholar
• Yamamoto M, Kondo I, Ogawa N, Asanuma M, Yamashita Y, Mizuno Y: Genetic association between susceptibility to Parkinson’s disease and alpha1-antichymotrypsin polymorphism. Brain Res 759: 153–155, 1997.
   PubMedGoogle Scholar
• Costa P, Checkoway H, Levy D, Smith-Weller T, Franklin GM, Swanson PD, Costa LG: Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease. Am J Med Genetics 74: 154–156, 1997.
   PubMed Web of Science ®Google Scholar
• Takakubo F, Yamamoto M, Ogawa N, Yamashita Y, Mizuno Y, Kondo I: Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson’s disease. J of Neural Transm—Gen Section 103: 843–849, 1996.
   PubMedGoogle Scholar
• Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276: 2045–2047, 1997.
   PubMed Web of Science ®Google Scholar
• Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T: Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sciences USA 90: 11282–11286, 1993.
   PubMed Web of Science ®Google Scholar
• Zhou W, Hurlbert M, Schaack J, Prasad K, Freed C: Overexpression of human α-synuclein increases dopamine neuron sensitivity to 6-hydroxydopamine. J Neurosci. submitted.
   Google Scholar
• Chen P, Jiang X, Forna L, Dimonte D, Tanner C, Langston J: Absence of mutation in the coding region of the alpha-synuclein gene in pathologically proven Parkinson’s disease. In Press.
   Google Scholar
• Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605–608, 1998.
   PubMed Web of Science ®Google Scholar
• Coyle JT, Puttfarcken P: Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689–695, 1993.
   PubMed Web of Science ®Google Scholar
• Parker WD, Jr., Swerdlow RH: Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genetics 62: 758–762, 1998.
   PubMed Web of Science ®Google Scholar
• Cooper JM, Schapira AH: Mitochondrial dysfunction in neurodegeneration. J Bioenerg Biomembr 29: 175–183, 1997.
   PubMed Web of Science ®Google Scholar
• Bowling A, Beal M: Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 56: 1151–1171, 1995.
   PubMed Web of Science ®Google Scholar
• Mann V, Cooper J, Krige D, Daniel S, Shapira A, Marsden C: Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease. Brain 115: 333–342, 1992.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD: Increased nigral iron content in postmortem parkinsonian brain [letter]. Lancet 2: 1219–1220, 1987.
   PubMed Web of Science ®Google Scholar
• Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA: Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease [published erratum appears in Neurology 45:1420, 1995. Neurology 45: 1138–1143, 1995.
   PubMed Web of Science ®Google Scholar
• Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB: Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520, 1989.
   PubMed Web of Science ®Google Scholar
• Perry TL, Godin DV, Hansen S: Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305–310, 1982.
   PubMed Web of Science ®Google Scholar
• Sofic E, Lange KW, Jellinger K, Riederer P: Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142: 128–230, 1992.
   PubMed Web of Science ®Google Scholar
• Ambani LM, Van Woert MH, Murphy S: Brain peroxidase and catalase in Parkinson disease. Arch Neurol 32: 114–118, 1975.
   PubMed Web of Science ®Google Scholar
• Kish SJ, Morito C, Hornykiewicz O: Glutathione peroxidase activity in Parkinson’s disease brain. Neurosci Lett 58: 343–346, 1985.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD: Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52: 381–389, 1989.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD: Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study [published erratum appears in Mov Disord 9:380, 1994. Movement Disord 9: 92–97, 1994.
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramos J, Overvik E, Ames B: A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson’s disease brain. Neurodegeneration 3: 197–204, 1994.
   Google Scholar
• The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183, 1993.
   PubMed Web of Science ®Google Scholar
• Fahns A: High-dosage antioxidants in early Parkinson’s disease. Arch Neurol 45: 810a, 1988.
   Google Scholar
• Smith TS, Parker Jr, WD, Bennett Jr JP: L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport 5: 1009–1011, 1994.
   PubMedGoogle Scholar
• Ogawa N, Asanuma M, Kondo Y, Kawada Y, Yamamoto M, Mori A: Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 171: 55–58, 1994.
   PubMed Web of Science ®Google Scholar
• Spencer JP, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, Jenner P, Lees AJ, Marsden DC, Halliwell B: Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett 353: 246–250, 1994.
   PubMed Web of Science ®Google Scholar
• Graham DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633–643, 1978.
   PubMed Web of Science ®Google Scholar
• Sax DS, Tarsy D: Side-effects of L-dopa. N Eng J Med 285: 1033–1037, 1971.
   PubMedGoogle Scholar
• Pentland B, Matthews D, Mawdsley C: Parkinson’s disease: Long-term results of levodopa therapy. Scott Med J 27: 284–287, 1982.
   PubMedGoogle Scholar
• Kaye JA, Feldman RG: The role of L-dopa holiday in the long-term management of Parkinson’s disease. Clin Neuropharmacol 9: 1–13, 1986.
   Google Scholar
• Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J: The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann of Neurol 38: 771–777, 1995.
   PubMed Web of Science ®Google Scholar
• Mytilineou C, Radcliffe PM, Olanow CW: L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J of Neurochem 68: 434–436, 1997.
   PubMedGoogle Scholar
• Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann of Neurol 39: 29–36, 1996.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann of Neurol 39: 37–45, 1996.
   PubMed Web of Science ®Google Scholar
• Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114: 2283–2301, 1991.
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM: Parkinson’s disease. First of two parts. N Eng J Med 339: 1044–1053, 1998.
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM: Parkinson’s disease. Second of two parts. N Eng J Med 339: 1130–1043, 1998.
   PubMed Web of Science ®Google Scholar
• Martin J: Molecular basis of the neurodegenerative disorders. N Eng J Med 340: 1970–1980, 1999.
   PubMed Web of Science ®Google Scholar
• Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 59: 527–605, 1979.
   PubMed Web of Science ®Google Scholar
• Ames B, Shigenaga M, Hagan T: Oxidants, antioxidants, and the degenerative disease of aging. Proc Natl Acad Sci USA 90: 7915–7922, 1993.
   PubMed Web of Science ®Google Scholar
• Chan PH, Fishman RA: Transient formation of superoxide radicals in polyunsaturated fatty acid-induced brain swelling. J Neurochem 35: 1004–1007, 1980.
   PubMed Web of Science ®Google Scholar
• Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620–1624, 1990.
   PubMed Web of Science ®Google Scholar
• Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J: NMDA-dependent superoxide production and neurotoxicity. Nature 364: 535–537, 1993.
   PubMed Web of Science ®Google Scholar
• Kiyosawa H, Suko M, Okudaira H, Murata K, Miyamoto T, Chung MH, Kasai H, Nishimura S: Cigarette smoking induces formation of 8-hydroxydeoxyguanosine, one of the oxidative DNA damages in human peripheral leukocytes. Free Rad Res Commun 11: 23–27, 1990.
   PubMed Web of Science ®Google Scholar
• Reznick AZ, Cross CE, Hu ML, Suzuki YJ, Khwaja S, Safadi A, Motchnik PA, Packer L, Halliwell B: Modification of plasma proteins by cigarette smoke as measured by protein carbonyl formation. Biochem J 286: 607–611, 1992.
   PubMed Web of Science ®Google Scholar
• Schectman G, Byrd JC, Hoffmann R: Ascorbic acid requirements for smokers: analysis of a population survey. Am J Clin Nutr 53: 1466–1470, 1991.
   PubMed Web of Science ®Google Scholar
• Duthie GG, Arthur JR, James WP: Effects of smoking and vitamin E on blood antioxidant status. Am J Clin Nutr 53: 1061S–1063S, 1991.
   PubMed Web of Science ®Google Scholar
• Winterbourn CC: Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett 82–83: 969–974, 1995.
   PubMed Web of Science ®Google Scholar
• Ames BN, Profet M, Gold LS: Dietary pesticides (99.99% all natural). Proc Natl Acad Sci USA 87: 7777–7781, 1990.
   PubMed Web of Science ®Google Scholar
• Gold LS, Slone TH, Stern BR, Manley NB, Ames BN: Rodent carcinogens: setting priorities. Science 258: 261–265, 1992.
   PubMed Web of Science ®Google Scholar
• Guyton A: “Blood Flow through Special Areas of the Body. Textbook of Medical Physiology.” 4th ed. Philadelphia: W.B. Saunders, pp 367–378, 1971.
   Google Scholar
• Boveris A, Chance B: The mitochondrial generation of hydrogen peroxide: general properties and the effect of hyperbaric oxygen. Biochem J 134: 707–716, 1973.
   PubMed Web of Science ®Google Scholar
• Marttila RJ, Lorentz H, Rinne UK: Oxygen toxicity protecting enzymes in Parkinson’s disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86: 321–331, 1988.
   PubMed Web of Science ®Google Scholar
• Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD: A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692–697, 1989.
   PubMed Web of Science ®Google Scholar
• Dexter D, Jenner P, Schapira A, Marsden C: Alterations in levels of iron, ferritin and other trace metals in neurodegenerative diseases affecting basal ganglia. Ann Neurol 32: S94–S100, 1992.
   Google Scholar
• Bondy SC: The relation of oxidative stress and hyperexcitation to neurological disease. Proc Soc Exp Biol Med 208: 337–345, 1995.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Srinivasan SK, Baxi MD: Oxidative stress and antioxidant therapy in Parkinson’s disease. Prog Neurobiol 48: 1–19, 1996.
   PubMedGoogle Scholar
• Halliwell B: Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson’s disease, Alzheimer’s disease, traumatic injury or stroke? Acta Neurol Scand Sup 126: 23–33, 1989.
   PubMedGoogle Scholar
• Olanow CW: Oxidation reactions in Parkinson’s disease. Neurology 40:Sup 32–37; Disc 37–39, 1990.
   Google Scholar
• Vatassery GT, Brin MF, Fahn S, Kayden HJ, Traber MG: Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats. J Neurochem 51: 621–623, 1988.
   PubMed Web of Science ®Google Scholar
• Pillai SR, Traber MG, Steiss JE, Kayden HJ, Cox NR: Alpha-tocopherol concentrations of the nervous system and selected tissues of adult dogs fed three levels of vitamin E. Lipids 28: 1101–1105, 1993.
   PubMedGoogle Scholar
• Cadet JL, Katz M, Jackson-Lewis V, Fahn S: Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476: 10–15, 1989.
   PubMed Web of Science ®Google Scholar
• Pappert EJ, Tangney CC, Goetz CG, Ling ZD, Lipton JW, Stebbins GT, Carvey PM: Alpha tocopherol in the ventricular cerebrospinal fluid of Parkinson’s disease patients: Dose response study and correlation with plasma levels. Neurology 47: 1037–1042, 1996.
   PubMed Web of Science ®Google Scholar
• Vatassery GT, Fahn S, Kuskowski MA: Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 50: 1900–1902, 1998.
   PubMed Web of Science ®Google Scholar
• Krinsky N: Antioxidant functions of carotenoids. Free Radical Biol Med 7: 617–635, 1989.
   PubMed Web of Science ®Google Scholar
• Zhang LX, Cooney RV, Bertram JS: Carotenoids up-regulate connexin-43 gene expression independent of their provitamin A or antioxidant properties. Cancer Res 52: 5707–5712, 1992.
   PubMed Web of Science ®Google Scholar
• Hazuka M, Edwards-Prasad J, Newman F, Kinzie JJ, Prasad KN: Beta-carotene induces morphological differentiation and decreases adenylate cyclase activity in melanoma cells in culture. J Am Coll Nutr 9: 143–149, 1990.
   PubMed Web of Science ®Google Scholar
• Meyskens Jr FL: Role of vitamin A and its derivatives in the treatment of human cancer. In Prasad KN, Santamaria L, Williams RM (eds). “Nutrients in Cancer Prevention and Treatment.” Totowa, New Jersey: Humana Press, pp 349–362, 1995.
   Google Scholar
• Carter CA, Pogribny M, Davidson A, Jackson CD, McGarrity LJ, Morris SM: Effects of retinoic acid on cell differentiation and reversion towards normal in human endometrial adenocarcinoma (RL95-2) cells. Anticancer Res 16: 17–24, 1996.
   PubMed Web of Science ®Google Scholar
• Vile GF, Winterbourn CC: Inhibition of adriamycin promoted microsomal lipid peroxidation by β-carotene, α-tocopherol and retinal at high and low oxygen partial pressure. FEBS Lett 238: 353–356, 1988.
   PubMed Web of Science ®Google Scholar
• McCay PB: Vitamin E: Interactions with free radicals and ascorbate. Ann Rev Nutr 5: 323–340, 1985.
   PubMed Web of Science ®Google Scholar
• Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp D, Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAFI/CIPI via C/EBPβ. Nat Med 3: 1233–1241, 1997.
   PubMed Web of Science ®Google Scholar
• Ingold KU, Burton GW, Foster DO, Hughes L, Lindsay DA, Webb A: Biokinetics of and discrimination between dietary RRR- and SRR-alpha-tocopherols in the male rat. Lipids 22: 163–172, 1987.
   PubMed Web of Science ®Google Scholar
• Prasad K, Edwards-Prasad J: Vitamin E and cancer prevention: Recent advances and future potentials. J Am Coll Nutr 11: 487–500, 1992.
   PubMed Web of Science ®Google Scholar
• Prasad K, Edwards-Prasad J: Effect of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. Cancer Res 42: 550–555, 1982.
   PubMed Web of Science ®Google Scholar
• Schwartz JL: Molecular and biochemical control of tumor growth following treatment with carotenoids or tocopherols. In: Prasad KN, Santamaria L, Williams RM (eds). “Nutrients in Cancer Prevention and Treatment.” New Jersey: Humana Press, pp 287–316, 1995.
   Google Scholar
• Helson L, Verma M, Helson C: Vitamin E and human neuroblastoma. In: Meyskens Jr F, Prasad K (eds). “Modulation and Mediation of Cancer Cells by Vitamins.” Basel: Karger, pp 258–265, 1983.
   Google Scholar
• Witschi A, Reddy S, Stofer B, Lauterburg BH: The systemic availability of oral glutathione. Eur J Clin Pharmacol 43: 667–669, 1992.
   PubMed Web of Science ®Google Scholar
• Niki E: Mechanisms and dynamics of antioxidant action of ubiquinol. Mol Asp Med 18: S63–S70, 1997.
   Google Scholar
• Niki E: Interaction of ascorbate and α-tocopherol. Ann N York Acad Sci 498: 186–199, 1987.
   PubMed Web of Science ®Google Scholar
• Stoyanovsky DA, Osipov AN, Quinn PJ, Kagan VE: Ubiquinone-dependent recycling of vitamin E radicals by superoxide. Arch Biochem Biophy 323: 343–351, 1995.
   PubMed Web of Science ®Google Scholar
• Hiramatsu M, Velasco RD, Wilson DS, Packer L: Ubiquinone protects against loss of tocopherol in rat liver microsomes and mitochondrial membranes. Res Commun Chem Pathol Pharmacol 72: 231–241, 1991.
   PubMedGoogle Scholar
• Chen RS, Huang CC, Chu NS: Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 37: 212–218, 1997.
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Birkmayer J, Vrecko C, Paletta B, Reschenhofer E, Ott E: Nicotnamide adenine dinucleotide (NADH) as medication for Parkinson’s disease: Experience with 415 patients. Trends Clin Neuropharmacol 4: 7–24, 1990.
   Google Scholar
• Birkmayer W, Birkmayer J, Vrecko K, Paletta B: The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in Parkinson’s patients. In Strifler M, Korezyn A, Melamed E, Youdin M (eds). “Parkinson’s Disease: Anatomy, Pathology, and Therapy.” New York: Raven Press, 545–549, 1990.
   Google Scholar
• Vrecko K, Birkmayer J, Krainz J: Stimulation of dopamine biosynthesis in cultured PC-12 pheochromocytoma cells by coenzyme nicotinamide adenine dinucleotide (NADH). J Neurotransmission 5: 147–156, 1993.
   Google Scholar
• Prasad K, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson W: Modification of the effect of tamoxifen, cis-platin, DTIC and interferon-α2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer 22: 233–245, 1994.
   PubMed Web of Science ®Google Scholar
• Prasad K, Kumar R: Effect of individual antioxidant vitamins alone and in combination on growth and differentiation of human non-tumorigenic and tumorigenic parotid acinar cells in culture. Nutr Cancer 26: 11–19, 1996.
   PubMed Web of Science ®Google Scholar
• Brumas V, Hacht B, Filella M, Berthon G: Can N-acetyl-L-cysteine affect zinc metabolism when used as a paracetamol antidote? Agents & Actions 36: 278–288, 1992.
   PubMedGoogle Scholar
• Hjortso E, Fomsgaard JS, Fogh-Andersen N: Does N-acetylcysteine increase the excretion of trace metals (calcium, magnesium, iron, zinc and copper) when given orally? Eur J Clin Pharmacol 39: 29–31, 1990.
   PubMedGoogle Scholar